Table 2.
Meta-analysis results using calculated unadjusted ORs
| Analysis for unadjusted mortality data | Studies (N) | Calculated OR (95% CI) |
|---|---|---|
| Totally high-risk patient populations | 8 | 5.85 (3.69, 9.26); I2 = 19.8% |
| Low risk of bias | 6 | 5.07 (3.38, 7.59); I2 = 0.0% |
| CS infection comparator | 5 | 5.24 (2.65, 10.37); I2 = 32.1% |
| No CR infection comparator | 3 | 7.02 (3.33, 14.80); I2 = 18.4% |
| No infection comparator | 2 | 24.76 (4.14, 148.00); I2 = 71.4% |
| In-hospital/≤30-day mortality | 4 | 6.08 (3.83, 9.66); I2 = 0.0% |
| Longer-term (> 30 days) mortality | 5 | 6.56 (2.81, 15.33); I2 = 51.3% |
| Italy | 3 | 5.86 (3.65, 9.41); I2 = 0.0% |
| USA | 5 | 5.40 (2.58, 11.30); I2 = 34.1% |
| Partially and totally high-risk patient populations | 14 | 4.13 (2.70, 6.31); I2 = 71.5% |
| Low risk of bias | 9 | 3.94 (2.32, 6.68); I2 = 71.4% |
| CS infection comparator | 10 | 3.39 (2.11, 5.45); I2 = 70.2% |
| No CR infection comparator | 3 | 7.02 (3.33, 14.80); I2 = 18.4% |
| No infection comparator | 3 | 13.39 (4.09, 43.87); I2 = 75.0% |
| In-hospital/≤30-day mortality | 10 | 3.74 (2.37, 5.89); I2 = 74.2% |
| Longer-term (> 30 days) mortality | 5 | 6.56 (2.81, 15.33); I2 = 51.3% |
| CRKP studies only | 12 | 4.68 (3.03, 7.23); I2 = 61.0% |
| CRPA studies only | 2 | 2.25 (0.84, 6.03); I2 = 77.6% |
| Italy | 5 | 4.21 (2.17, 8.14); I2 = 73.3% |
| USA | 9 | 3.83 (2.54, 5.76); I2 = 28.1% |
CI Confidence interval, CRKP Carbapenem-resistant Klebsiella pneumoniae, CRPA Carbapenem-resistant Pseudomonas aeruginosa, CS Carbapenem-susceptible, N Number, OR Odds ratio